Today’s Top Three in Pharma 060209 posted on June 2, 2009Sepracor's experimental epilepsy drug (Stedesa) proceeds to FDA review. STEDESA, a new chemical entity, is a novel voltage-gated sodium channel blocker. STEDESA has been studied in three Phase …Continue Reading about Today’s Top Three in Pharma 060209 →